Treatment with an anti-DLL4 antibody targeted to macrophages through lipid coated nanoparticles inhibited production of inflammatory cytokines, decreased macrophage accumulation, and decreased progression of atherosclerosis in CKD mice. Here, DLL4 is linked to chronic kidney disease.